Localized Cylindrical Drug Delivery to Prevent Vascular Restenosis
The Need: Addressing Vascular Restenosis with Extended Drug Delivery
Vascular restenosis poses a significant medical challenge in the United States, particularly in cases of coronary artery disease treated with bypass grafting. The current methods involve using drug-loaded polymer formulations to deliver compounds locally and inhibit intimal hyperplasia. However, the existing water-based techniques have limited half-lives, leading to restenosis over time, even in transplanted arteries. There is a pressing need for a novel preventive measure to overcome these limitations and provide sustained drug release for extended periods, ultimately reducing restenosis without adverse effects on the treated arteries.
The Technology: Extended Drug Delivery Cuffs
The technology presented involves shaped, hollow polymeric cylinders or cuffs designed to encircle and slowly deliver anti-restenotic drugs, such as rapamycin and paclitaxel, for prolonged periods (months to years). The cuffs are made of biocompatible and biodegradable polymers, particularly Poly(caprolactone) (PCL) and Poly(ethylene glycol) (PEG). These cuffs feature hydrophobic or semi-hydrophobic carriers to maintain the drugs' bioactivity, engineered porosity for controlled drug release, and a relatively high drug volume to sustain optimal drug concentrations over extended durations.
In summary, our extended drug delivery cuffs represent a breakthrough solution to address the pressing issue of vascular restenosis. By providing sustained and targeted drug release over extended periods, this technology has the potential to revolutionize cardiovascular treatments, improving patient outcomes and reducing the burden of restenosis-related healthcare costs.